small molecule

DEXTENZA

DEXAMETHASONE

Loss of exclusivityApril 2041latest FDA-listed patent expiry

CompanyOcular Therapeutix →See this company's full patent-cliff portfolio

Drug detail

Brand name	DEXTENZA
Active ingredient	DEXAMETHASONE
Strength	0.4MG
Dosage form	INSERT
Route	OPHTHALMIC
Modality	Small molecule
FDA approval	November 2018
Marketing status	RX

Listed patents

Patent	Expires	Type
12144889	April 2041	use U-1680
11458041	November 2037	use U-3455
12150896	October 2036	use U-3455
8409606	May 2030	product
8563027	February 2030	use U-2487

Regulatory exclusivity

Code	Expires
NPP	April 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.